KORU Medical Systems Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2022

Basic earnings per share are computed on the weighted average of common shares outstanding during each year. Diluted earnings per share include only an increase in the weighted average shares by the common shares issuable upon exercise of employee and consultant stock options. See “NOTE 4 — STOCK-BASED COMPENSATION” for further detail.

Schedule of net income per common share


	Three Months Ended
	March 31,
	2022			2021

Net loss	$	(2,537,514	)	$	(1,276,138	)

Weighted Average Outstanding Shares:
Outstanding shares		44,667,977			43,960,936
Option shares includable		—	^(a)		—	^(a)
Total		44,667,977			43,960,936

Net loss per share
Basic	$	(0.06	)	$	(0.03	)
Diluted	$	(0.06	)	$	(0.03	)

__________

(a)

For the three months ended March 31, 2022 and March 31, 2021, option shares of 346,020 and 183,681 were not included as the impact is anti-dilutive. For the three months ended March 31, 2022 and March 31, 2021, restricted shares of 1,000,000 and zero respectively, were not included as the impact is anti-dilutive.

Schedule of net sales by geography

The following table summarizes net sales by geography for the three months ended March 31, 2022, and 2021:

Schedule of net sales by geography

	Three Months Ended March 31,				% of Total Net Sales
	2022		2021		2022		2021
Net Sales
Domestic	$	5,301,388	$	4,446,789		84.9%	81.9%
International		942,942		984,162		15.1%	18.1%
Total Net Sales	$	6,244,330	$	5,430,951